Show simple item record

dc.contributor.authorBridgemohan, Carolyn
dc.contributor.authorCochran, David E.
dc.contributor.authorZimmerman, Andrew W.
dc.contributor.authorChoueiri, Roula N.
dc.contributor.authorFrazier, Jean A.
dc.date2022-08-11T08:09:53.000
dc.date.accessioned2022-08-23T16:47:51Z
dc.date.available2022-08-23T16:47:51Z
dc.date.issued2019-08-02
dc.date.submitted2019-09-16
dc.identifier.citation<p>Front Integr Neurosci. 2019 Aug 2;13:31. doi: 10.3389/fnint.2019.00031. eCollection 2019. <a href="https://doi.org/10.3389/fnint.2019.00031">Link to article on publisher's site</a></p>
dc.identifier.issn1662-5145 (Linking)
dc.identifier.doi10.3389/fnint.2019.00031
dc.identifier.pmid31427932
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41158
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractBackground: Early identification and treatment of individuals with autism spectrum disorder (ASD) improves outcomes, but specific evidence needed to individualize treatment recommendations is lacking. Biomarkers that could be routinely measured within the clinical setting could potentially transform clinical care for patients with ASD. This demonstration project employed collection of biomarker data during regular autism specialty clinical visits and explored the relationship of biomarkers with clinical ASD symptoms. Methods: Eighty-three children with ASD, aged 5-10 years, completed a multi-site feasibility study integrating the collection of biochemical (blood serotonin, urine melatonin sulfate excretion) and clinical (head circumference, dysmorphology exam, digit ratio, cognitive and behavioral function) biomarkers during routine ASD clinic visits. Parents completed a demographic survey and the Aberrant Behavior Checklist-Community. Cognitive function was determined by record review. Data analysis utilized Wilcoxon two-sample tests and Spearman correlations. Results: Participants were 82% male, 63% White, 19% Hispanic, with a broad range of functioning. Group means indicated hyperserotonemia. In a single regression analysis adjusting for race and median household income, higher income was associated with higher levels of blood serotonin and urine melatonin sulfate excretion levels (p = 0.004 and p = 0.04, respectively). Melatonin correlated negatively with age (p = 0.048) and reported neurologic problems (p = 0.02). Dysmorphic status correlated with higher reported stereotyped behavior (p = 0.02) and inappropriate speech (p = 0.04). Conclusion: This demonstration project employed collection of multiple biomarkers, allowed for examination of associations between biochemical and clinical measures, and identified several findings that suggest direction for future studies. This clinical research model has promise for integrative biomarker research in individuals with complex, heterogeneous neurodevelopmental disorders such as ASD.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=31427932&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © 2019 Bridgemohan, Cochran, Howe, Pawlowski, Zimmerman, Anderson, Choueiri, Sices, Miller, Ultmann, Helt, Forbes, Farfel, Brewster, Frazier and Neumeyer on behalf of the Autism Consortium Biomarkers Study Clinicians. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectASD
dc.subjectautism
dc.subjectbiomarkers
dc.subjectclinical research
dc.subjectdysmorphology
dc.subjectmelatonin
dc.subjectserotonin
dc.subjectBiological Factors
dc.subjectCongenital, Hereditary, and Neonatal Diseases and Abnormalities
dc.subjectDiagnosis
dc.subjectMental Disorders
dc.subjectNervous System
dc.subjectNeurology
dc.subjectNeuroscience and Neurobiology
dc.subjectPediatrics
dc.subjectPsychiatry
dc.subjectPsychiatry and Psychology
dc.titleInvestigating Potential Biomarkers in Autism Spectrum Disorder
dc.typeJournal Article
dc.source.journaltitleFrontiers in integrative neuroscience
dc.source.volume13
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4963&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3947
dc.identifier.contextkey15341048
refterms.dateFOA2022-08-23T16:47:51Z
html.description.abstract<p>Background: Early identification and treatment of individuals with autism spectrum disorder (ASD) improves outcomes, but specific evidence needed to individualize treatment recommendations is lacking. Biomarkers that could be routinely measured within the clinical setting could potentially transform clinical care for patients with ASD. This demonstration project employed collection of biomarker data during regular autism specialty clinical visits and explored the relationship of biomarkers with clinical ASD symptoms.</p> <p>Methods: Eighty-three children with ASD, aged 5-10 years, completed a multi-site feasibility study integrating the collection of biochemical (blood serotonin, urine melatonin sulfate excretion) and clinical (head circumference, dysmorphology exam, digit ratio, cognitive and behavioral function) biomarkers during routine ASD clinic visits. Parents completed a demographic survey and the Aberrant Behavior Checklist-Community. Cognitive function was determined by record review. Data analysis utilized Wilcoxon two-sample tests and Spearman correlations.</p> <p>Results: Participants were 82% male, 63% White, 19% Hispanic, with a broad range of functioning. Group means indicated hyperserotonemia. In a single regression analysis adjusting for race and median household income, higher income was associated with higher levels of blood serotonin and urine melatonin sulfate excretion levels (p = 0.004 and p = 0.04, respectively). Melatonin correlated negatively with age (p = 0.048) and reported neurologic problems (p = 0.02). Dysmorphic status correlated with higher reported stereotyped behavior (p = 0.02) and inappropriate speech (p = 0.04).</p> <p>Conclusion: This demonstration project employed collection of multiple biomarkers, allowed for examination of associations between biochemical and clinical measures, and identified several findings that suggest direction for future studies. This clinical research model has promise for integrative biomarker research in individuals with complex, heterogeneous neurodevelopmental disorders such as ASD.</p>
dc.identifier.submissionpathoapubs/3947
dc.contributor.departmentDepartment of Pediatrics, Division of Pediatric Neurology
dc.contributor.departmentDepartment of Pediatrics, Division of Development and Behavioral Pediatrics
dc.contributor.departmentDepartment of Psychiatry
dc.contributor.departmentEunice Kennedy Shriver Center
dc.source.pages31


Files in this item

Thumbnail
Name:
fnint_13_00031.pdf
Size:
320.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2019 Bridgemohan, Cochran, Howe, Pawlowski, Zimmerman, Anderson, Choueiri, Sices, Miller, Ultmann, Helt, Forbes, Farfel, Brewster, Frazier and Neumeyer on behalf of the Autism Consortium Biomarkers Study Clinicians. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Except where otherwise noted, this item's license is described as Copyright © 2019 Bridgemohan, Cochran, Howe, Pawlowski, Zimmerman, Anderson, Choueiri, Sices, Miller, Ultmann, Helt, Forbes, Farfel, Brewster, Frazier and Neumeyer on behalf of the Autism Consortium Biomarkers Study Clinicians. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.